Sonomotion Inc.

Emerald Hills, CA · Founded 2012 · Medtech · Private

Break Wave, an office-based ultrasound lithotripsy device using multi-cycle low-amplitude ultrasound pulses to fracture kidney and ureteral stones without anesthesia

Claim this profile

Follows are private to you and power your alerts

Updated Oct 23, 2026 · sonomotion.com

Sector: Medtech
Headquarters: Emerald Hills, CA
Founded: 2012
Latest Form D: $11.5M, Apr 2022
Total capital: $31.8M

Federal grants: $12.5M; 15 awards · 2015–2026; Rank in peer group#178 of 538
Private capital raised: $19.4M; 4 Form D · last Apr 2022; 54 months since last filing
Federal contracts: None on recordNo federal contract awards found.
Granted patents: 2; 4 pending · first 2020; Rank in peer group#190 of 538

Capital timeline

Latest events

Jun 2026Federal grantHealth and Human S · Phase II · Break Wave lithotripsy to fragment large kidney stones$960K
Feb 2025Federal grantHealth and Human S · Phase II · Break Wave lithotripsy to fragment large kidney stones$278K
Apr 2022Private capital raisedForm D · SEC · 4th filing$11.5M
Sep 2021Federal grantHealth and Human S · Phase II · Commercial readiness of Break Wave - The SonoMotion Office-Based Lithotripsy Solution$400K
Apr 2021Federal grantHealth and Human S · Phase II · First-In-Human Feasibility Trial of Break Wave - The Office-Based Lithotripsy Solution$970K
Mar 2020Federal grantHealth and Human S · Phase II · First-In-Human Feasibility Trial of Break Wave - The Office-Based Lithotripsy Solution$997K
Apr 2019Private capital raisedForm D · SEC · 3rd filing$3.3M
Apr 2017Private capital raisedForm D · SEC · 2nd filing$4.5M
Jul 2016Private capital raisedForm D · SEC · 1st filing$100K

Show 10 earlier federal awards

Apr 2019Federal grantHealth and Human S · Phase II · First-In-Human Feasibility Trial of Break Wave - The Office-Based Lithotripsy Solution$3M
Apr 2019Federal grantHealth and Human S · Phase II · First-In-Human Feasibility Trial of Break Wave - The Office-Based Lithotripsy Solution$1.0M
May 2018Federal grantHealth and Human S · Phase II · Burst Wave Lithotripsy for the Treatment of Ureteral Calculi$685K
Apr 2017Federal grantHealth and Human S · Phase II · Burst Wave Lithotripsy for the Treatment of Ureteral Calculi$770K
Jan 2017Federal grantHealth and Human S · Phase II · Non-invasive Promotion of Clearance of Kidney Stones and Fragments$763K
Sep 2016Federal grantHealth and Human S · Phase II · Non-invasive Promotion of Clearance of Kidney Stones and Fragments$258K
Apr 2016Federal grantHealth and Human S · Phase II · Burst Wave Lithotripsy for the Treatment of Ureteral Calculi$208K
Mar 2016Federal grantHealth and Human S · Phase II · Non-invasive Promotion of Clearance of Kidney Stones and Fragments$737K
Feb 2016Federal grantHealth and Human S · Phase II · Non invasive Promotion of Clearance of Kidney Stones and Fragments$1.2M
Jul 2015Federal grantHealth and Human S · Phase II · Non-invasive Promotion of Clearance of Kidney Stones and Fragments$225K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Federal first

12months

from Sonomotion Inc.’s first federal award to its first private round.

First federal award · Jul 2015: Health and Human S · $225K
First Form D · Jul 2016: $100K · 1st Form D
Awards before first raise: 4 awards

An association in public records, not a cause or a prediction.

Standing among 538 peers

Line = median

Medtech · Device

Federal grants#178 · top 33%
Granted patents#190 · top 35%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

Researcher links verified by same-company patents and grants

Michael BaileyResearcherDirectorLinked by 1 patent
Oren LevyResearcherExecutive Officer, DirectorLinked by $12.5M in grants as PI
Barbrina DunmireDirectorNamed in SEC Form D filings
Jeff BarnesDirectorNamed in SEC Form D filings
Paul Douglas CorlExecutive OfficerNamed in SEC Form D filings
Takashi FukiyamaDirectorNamed in SEC Form D filings

Show all 7 people

Takashi FukuyamaDirectorNamed in SEC Form D filings

What it has protected

USPTO · 2 granted of 6

Jun 8, 2021GrantedModulation Of Transducer Amplitude And Phase Distributions For Controlled Application Of Radiation Force To An ObjectUSPTOUS 11,026,706
Jun 2, 2020GrantedBroadly Focused Ultrasonic Propulsion Probes, Systems, And MethodsUSPTOUS 10,667,831
Oct 17, 2019PendingTargeting Methods And Devices For Non-invasive Therapy DeliveryUSPTOApplication 16383386

Show all 6 patent records

Modulation Of Transducer Amplitude And Phase Distributions For Controlled Application Of Radiation Force To An ObjectJun 8, 2021 · US 11,026,706Granted
Broadly Focused Ultrasonic Propulsion Probes, Systems, And MethodsJun 2, 2020 · US 10,667,831Granted
Targeting Methods And Devices For Non-invasive Therapy DeliveryOct 17, 2019 · Application 16383386Pending
Ultrasound Devices Incorporating Phase Change Materials And Systems And Methods Using The DevicesApplication PCTUS2017056635Pending
Ultrasound Devices Incorporating Phase Change Materials And Systems And Methods Using The DevicesApplication 62409803Pending
Broadly Focused Ultrasonic Propulsion Probes, Systems, And MethodsApplication PCTUS2015056261Pending

MICROBEDX, INC.Similar federal contract value in Medtech · null in contracts
DEEPWAVE TECHNOLOGIES, INC.Similar federal contract value in Medtech · null in contracts
Peltier Technology Inc.Similar federal contract value in Medtech · null in contracts
CERVU, INCSimilar federal contract value in Medtech · null in contracts
CLINICAL SENSORS, INC.Similar federal contract value in Medtech · null in contracts
NEUROGAMI MEDICAL, INC.Similar federal contract value in Medtech · null in contracts

Regulatory activity · Medtech

Sector-level, not company-level

07 Jul 2026New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
30 Jun 2026Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
30 Jun 2026Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
29 Jun 2026Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
26 Jun 2026Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
26 Jun 2026Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through Oct 23, 2026. SBIR and STTR awards through Oct 21, 2026.